Medical News

[ In The Age Of Information, Physicians Are Still The Most Trusted Source For Parents Of Children With Cancer ]

In The Age Of Information, Physicians Are Still The Most Trusted Source For Parents Of Children With Cancer

Parents and adult caregivers of pediatric cancer patients prefer personal consultations with trusted health care providers over online sources for information about their child's illness, according to a University at Buffalo research study. Despite the accessibility of online medical information, the UB study found that parents not only distrusted information found through the Internet, they often feared what types of information they might encounter. "Respondents were telling us they were uncertain of the information online and that they were afraid of the unknown, " says study co-author Elizabeth Gage, PhD, professor of community health and health behavior in the UB School of Public Health and Health Professions. "They didn't want to run into stories about 'the worst case scenario.'" Gage, along with Christina Panagakis, a graduate student in sociology at UB, and colleagues at Roswell Park Cancer Institute, interviewed 41 parents of pediatric cancer patients in the U.

Vemurafenib Effective For Some Metastatic Melanoma Patients

Results from a phase II multi-center clinical trial involving 132 patients with previously treated BRAF V600-mutant metastatic melanoma, indicate that vemurafenib (PLX4032) - an oral BRAF inhibitor - offered a high rate of response in some patients. According to the researchers from the U.S. and Australia, including researchers at Moffitt Cancer Center in Tampa, Fla., over 50% of the study participants had positive, prolonged responses as well as a median survival of nearly 16 months. The study was published in the New England Journal of Medicine. Jeffrey S. Weber, M.D., Ph.D., director of the Donald A. Adam Comprehensive Melanoma Research Center at Moffitt, revealed that around 50% of melanomas contain the activating (V600) mutation threonine protein kinase B-RAF. However, for these patients treatment options are "limited.

Study Of Selenium Metabolism

Spanish and Danish researchers have developed a method for the in vivo study of the unknown metabolism of selenium, an essential element for living beings. The technique can help clarify whether or not it possesses the anti-tumour properties that have been attributed to it and yet have not been verified through clinical trials. "It is vox populi that doctors around the world recommend selenium supplements to complement traditional therapy against cancer and the AIDS virus but the truth is that the basics of these properties are not clear, " explains to SINC Justo Giner, a chemist from the University of Oviedo (Spain). "Even the general metabolism of selenium has not been completely cleared up, " adds Giner who, along with other researchers at the same university and the University of Pharmaceutical Sciences of Copenhagen (Denmark), has developed a new methodology for discovering how this element moves around living organisms.

New Evidence Of Cancer-Causing Agent Present In Gaseous Phase Of Cigarette Smoke

A team of researchers led by A. K. Rajasekaran, PhD, Director of the Nemours Center for Childhood Cancer Research, has shown that a key protein involved in cell function and regulation is stopped by a substance present in cigarette smoke. Their work is published online in the American Journal of Physiology - Lung Cell and Molecular Physiology. Cigarette smoke is well recognized as a cause of lung cancer and is associated with many other forms of cancer in adults. Cigarette smoke has more than 4, 000 components, many of which are linked to the development and progression of lung cancer. Evidence has shown secondhand smoke to be as dangerous as primary smoke due to its impact on the cells of the body. In the study, the authors found a cancer-causing agent called reactive oxygen species (ROS) present in the gaseous phase of cigarette smoke that has the ability to inhibit normal cell function.

Bisphosphonates May Have Protective Effect On Endometrial Cancer

Low bone density medications, such as Fosamax, Boniva and Actonel, may have a protective effect for endometrial cancer, according to a study at Henry Ford Hospital. Endometrial cancer affects more than 45, 000 women a year in the U.S., usually in their 60s, although it can occur before 40. A type of uterine cancer, it's the most commonly diagnosed gynecologic cancer, and there is no known preventive medication for women at high risk of developing it. "The results of the study suggest that use of low bone density medications may have a protective effect on endometrial cancer, or that women who take them get a less-aggressive cancer, " says Sharon Hensley Alford, Ph.D, lead author of the study, and a researcher in Public Health Services at Henry Ford Hospital. The classification for these medications is bisphosphonates.

Rocket: [100] [200]

Medical News © Nanda
Designer Damodar